IDT AustraliaASX:IDT Return-on-Tangible-Asset is -7.38% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 1,009 Drug Manufacturers companies, IDT Australia ranks worse than 82.26% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. IDT Australia's annualizedNet Income for the quarter that ended in Dec. 2025 was A$-2.64 Mil. IDT Australia's average total tangible assets for the quarter that ended in Dec. 2025 was A$35.73 Mil. Therefore, IDT Australia's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -7.38%.
The historical rank and industry rank for IDT Australia's Return-on-Tangible-Asset or its related term are showing as below:
ASX:IDT'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -44.34 Med: -14.19 Max: 6.65
Current: -16.86
During the past 13 years, IDT Australia's highest Return-on-Tangible-Asset was 6.65%. The lowest was -44.34%. And the median was -14.19%.
ASX:IDT's Return-on-Tangible-Asset is ranked worse than 82.26% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs ASX:IDT: -16.86
IDT Australia (ASX:IDT) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
IDT Australia Return-on-Tangible-Asset Related Terms
IDT Australia Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for IDT Australia's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IDT vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, IDT Australia's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDT Australia Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, IDT Australia's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where IDT Australia's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -7.38% mean?
IDT Australia (ASX:IDT) has a Return-on-Tangible-Asset of -7.38% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on IDT Australia and its competitors. According to the industry distribution chart, IDT Australia ranks #830 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 82.3%.
Is IDT Australia's Return-on-Tangible-Asset too high?
IDT Australia's current Return-on-Tangible-Asset is -7.38%. Based on the distribution chart, IDT Australia ranks #830 out of 1009 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does IDT Australia's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, IDT Australia ranks #830 out of 1009 companies for Return-on-Tangible-Asset. This places IDT Australia in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on IDT Australia and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDT Australia's current Return-on-Tangible-Asset is -7.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDT Australia stock overvalued right now?
Based on GuruFocus' analysis, IDT Australia (ASX:IDT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.17, compared to a current price of A$0.03 — trading 81.2% below its estimated fair value. The current Return-on-Tangible-Asset is -7.38%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For IDT Australia (ASX:IDT), the current Return-on-Tangible-Asset is -7.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services. The company operates in Australia, Asia, Europe, and the USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDT has been successfully added to your 